Evidence map›Paper›PMID 28765194›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2017

Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States.

Zheming Yu, Hamed Samavat, Allison M Dostal, Renwei Wang, Carolyn J Torkelson, Chung S Yang, Lesley M Butler, Thomas W Kensler, Anna H Wu, Mindy S Kurzer and 1 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05195918 phase1completednot on this mapstarted 2023, after this paper: background citation

Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect

TypeinterventionalSponsorHal ChapmanRan2023 to 2026Enrolled50ConditionsIdiopathic Pulmonary FibrosisArmsEGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone
NCT07149506 phase3enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

TypeinterventionalSponsorCARLOS FRANCISCO SAAVEDRA GARCIARan2025 to 2027Enrolled162ConditionsRadiation Dermatitis Acute, Radiation Dermatitis, Fibrosis, SkinArmsEpicatechin, Epigallocatechin Gallate (EGCG), Microcrystalline Cellulose NF (placebo), Saline (0.9% NaCl)
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Green tea (Camellia sinensis) for the prevention of cancer.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Natural Products Targeting Oxidative Stress-Inflammation Crosstalk in Endometriosis.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Zheming YuUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Hamed SamavatDepartment of Food Science & Nutrition, University of Minnesota, St. Paul, Minnesota.
Allison M DostalDepartment of Medicine, Division of Gastroenterology, Hepatology, & Nutrition, University of Minnesota, Minneapolis, Minnesota.
Renwei WangUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Carolyn J TorkelsonDepartment of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, Minnesota.
Chung S YangDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey.
Lesley M ButlerUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Thomas W KenslerUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Anna H WuDepartment of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California.
Mindy S KurzerDepartment of Food Science & Nutrition, University of Minnesota, St. Paul, Minnesota.
Jian-Min YuanUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. yuanj@upmc.edu.
University of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Prospective studies of cancer etiology and prevention in Shanghai and SingaporeR01CA144034 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2010 to 2014
$7.0M
Targeting Nrf2 for Cancer ChemopreventionR35CA197222 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KENSLER, THOMAS W · 2015 to 2021
$6.7M
Green Tea and Reduction of Breast Cancer RiskR01CA127236 · NCI · UNIVERSITY OF MINNESOTA · PI KURZER, MINDY SUSAN · 2008 to 2013
$5.7M
Cancer epidemiology cohorts in Shanghai and Singapore UM1CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2014 to 2018
$4.3M
Randomized trial of PEITC as a modifier of NNK metabolism in smokersR01CA122244 · NCI · UNIVERSITY OF MINNESOTA · PI HATSUKAMI, DOROTHY K, YUAN, JIAN-MIN · 2008 to 2012
$2.9M
Translational Research Training in Cancer Prevention and ControlT32CA186873 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kathryn H. Schmitz, Jian-Min Yuan · 2014 to 2026
$2.7M
Training Program in Nutrition and CancerT32CA132670 · NCI · UNIVERSITY OF MINNESOTA · PI ANDERSON, KRISTIN ELLEN · 2009 to 2013
$1.6M
NCI NIH HHS P30 CA047904NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA122244NCI NIH HHS R01 CA127236NCI NIH HHS R01 CA144034NCI NIH HHS R35 CA197222NCI NIH HHS T32 CA132670NCI NIH HHS T32 CA186873NCI NIH HHS UM1 CA182876
6 · The paper itself

Abstract

Liver injury effects of green tea-based products have been reported in sporadic case reports. However, no study has examined systematically such adverse effects in an unbiased manner. We examined the potential effects of a high, sustained oral dose of green tea extract (GTE) on liver injury measures in a randomized, placebo-controlled, double-blinded phase II clinical trial, which enrolled 1,075 women with the original aim to assess the effect of daily GTE consumption for 12 months on biomarkers of breast cancer risk. The current analysis examined the effect of GTE consumption on liver injury in 1,021 participants (513 in GTE and 508 in placebo arm) with normal baseline levels of liver enzymes. Among women in the GTE arm, alanine aminotransferase (ALT) increased by 5.4 U/L [95% confidence interval (CI), 3.6-7.1] and aspartate aminotransferase increased by 3.8 U/L (95% CI, 2.5-5.1), which were significantly higher than those among women in the placebo arm (both

Indexed as

AgedAlanine TransaminaseAntioxidantsAspartate AminotransferasesBiomarkers, TumorBreast NeoplasmsCatechinChemical and Drug Induced Liver InjuryDietary SupplementsDouble-Blind MethodFemaleHumansLiverLiver Function TestsMiddle AgedPlacebosAlanine TransaminaseAntioxidantsAspartate AminotransferasesBiomarkers, TumorCatechinPlacebosPlant ExtractsTea

Identifiers

PMID28765194
PMCPMC9257888
OpenAlexW2739571795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.